UNLABELLED: Although the role of CD4 T cells in tissue inflammation and organ injury resulting from ischemia and reperfusion injury (IRI) has been well documented, it remains unclear how CD4 T cells are activated and function in the absence of a specific antigen (Ag). We used a murine liver warm IRI model to determine first whether de novo Ag-specific CD4 T cell activation was required and then what its functional mechanism was. The critical role of CD4 T cells in liver immune activation against ischemia and reperfusion (IR) was confirmed in CD4 knockout mice and CD4 depleted wild-type mice. Interestingly, the inhibition of CD4 T cell activation without target cell depletion failed to protect livers against IRI, and this suggested that T cells function in liver IRI without Ag-specific de novo activation. To dissect the T cell functional mechanism, we found that CD154 blockade, but not interferon gamma (IFN-gamma) neutralization, inhibited local immune activation and protected livers from IRI. Furthermore, agonist anti-CD40 antibodies restored liver IRI in otherwise protected CD4-deficient hosts. Finally, fluorescence-activated cell sorting analysis of liver CD4 T cells revealed the selective infiltration of effector cells, which constitutively expressed a higher level of CD154 in comparison with their peripheral counterparts. IR triggered a significant liver increase in CD40 expression but not CD154 expression, and macrophages responded to toll-like receptor 4 and type I IFN stimulation to up-regulate CD40 expression. CONCLUSION: These novel findings provide evidence that CD4 T cells function in liver IRI via CD154 without de novo Ag-specific activation, and innate immunity-induced CD40 up-regulation may trigger the engagement of CD154-CD40 to facilitate tissue inflammation and injury.
UNLABELLED: Although the role of CD4 T cells in tissue inflammation and organ injury resulting from ischemia and reperfusion injury (IRI) has been well documented, it remains unclear how CD4 T cells are activated and function in the absence of a specific antigen (Ag). We used a murine liver warm IRI model to determine first whether de novo Ag-specific CD4 T cell activation was required and then what its functional mechanism was. The critical role of CD4 T cells in liver immune activation against ischemia and reperfusion (IR) was confirmed in CD4 knockout mice and CD4 depleted wild-type mice. Interestingly, the inhibition of CD4 T cell activation without target cell depletion failed to protect livers against IRI, and this suggested that T cells function in liver IRI without Ag-specific de novo activation. To dissect the T cell functional mechanism, we found that CD154 blockade, but not interferon gamma (IFN-gamma) neutralization, inhibited local immune activation and protected livers from IRI. Furthermore, agonist anti-CD40 antibodies restored liver IRI in otherwise protected CD4-deficient hosts. Finally, fluorescence-activated cell sorting analysis of liver CD4 T cells revealed the selective infiltration of effector cells, which constitutively expressed a higher level of CD154 in comparison with their peripheral counterparts. IR triggered a significant liver increase in CD40 expression but not CD154 expression, and macrophages responded to toll-like receptor 4 and type I IFN stimulation to up-regulate CD40 expression. CONCLUSION: These novel findings provide evidence that CD4 T cells function in liver IRI via CD154 without de novo Ag-specific activation, and innate immunity-induced CD40 up-regulation may trigger the engagement of CD154-CD40 to facilitate tissue inflammation and injury.
Authors: M J Burne; F Daniels; A El Ghandour; S Mauiyyedi; R B Colvin; M P O'Donnell; H Rabb Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808
Authors: Xiu-Da Shen; Bibo Ke; Yuan Zhai; Farin Amersi; Feng Gao; Dean M Anselmo; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Transplantation Date: 2002-08-15 Impact factor: 4.939
Authors: Xiu-Da Shen; Bibo Ke; Yuan Zhai; Feng Gao; Dean Anselmo; Charles R Lassman; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2003-02 Impact factor: 17.425
Authors: Marc de Perrot; Kevin Young; Yumiko Imai; Mingyao Liu; Thomas K Waddell; Stefan Fischer; Li Zhang; Shaf Keshavjee Journal: J Immunol Date: 2003-11-15 Impact factor: 5.422
Authors: Yuan Zhai; Bo Qiao; Feng Gao; Xiuda Shen; Andrew Vardanian; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Paul J Chestovich; Yoichiro Uchida; William Chang; Mark Ajalat; Charles Lassman; Robert Sabat; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Transplantation Date: 2012-03-15 Impact factor: 4.939
Authors: Benjamin H Friedman; Joshua H Wolf; Liqing Wang; Mary E Putt; Abraham Shaked; Jason D Christie; Wayne W Hancock; Kim M Olthoff Journal: Liver Transpl Date: 2012-02 Impact factor: 5.799
Authors: Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Nat Rev Gastroenterol Hepatol Date: 2012-12-11 Impact factor: 46.802
Authors: Rebecca A Sosa; Ali Zarrinpar; Maura Rossetti; Charles R Lassman; Bita V Naini; Nakul Datta; Ping Rao; Nicholas Harre; Ying Zheng; Roberto Spreafico; Alexander Hoffmann; Ronald W Busuttil; David W Gjertson; Yuan Zhai; Jerzy W Kupiec-Weglinski; Elaine F Reed Journal: JCI Insight Date: 2016-12-08